 |
|
Hypertriglyceridemia and Its Pharmacologic Treatment Among US Adults
Earl S. Ford, MD, MPH;
Chaoyang Li, MD, PhD;
Guixiang Zhao, MD, PhD;
William S. Pearson, PhD;
Ali H. Mokdad, PhD
Arch Intern Med. 2009;169(6):572-578.
Background Increasing evidence supports triglyceride (TG) concentration as a risk factor for cardiovascular disease. The prevalence of hypertriglyceridemia during a period of rising prevalence of obesity and its pharmacological treatment among US adults are poorly understood.
Methods We examined data for 5610 participants 20 years or older from the National Health and Nutrition Examination Surveys from 1999 to 2004.
Results The unadjusted prevalence (percentage [SE]) of a TG concentration of 150 mg/dL or higher (to convert triglycerides to millimoles per liter, multiply by 0.0113) was 33.1% (0.8%); a TG concentration of 200 mg/dL or higher, 17.9% (0.7%), a TG concentration of 500 mg/dL or higher, 1.7% (0.2%), and a TG concentration of 1000 mg/dL or higher, 0.4% (0.1%). Overall, 1.3% (0.2%) of participants used 1 of 3 prescription medications indicated to treat hypertriglyceridemia (ie, fenofibrate, gemfibrozil, or niacin); this percentage was 2.6% (0.4%) among participants with a TG concentration of 150 mg/dL or higher and 3.6% (0.7%) among participants with a TG concentration of 200 mg/dL or higher.
Conclusions Among US adults, hypertriglyceridemia is common. Until the benefits of treating hypertriglyceridemia that is not characterized by extreme elevations of TG concentration with medications are incontrovertible, therapeutic lifestyle change remains the preferred treatment.
Author Affiliations: Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
In This Issue of Archives of Internal Medicine
Arch Intern Med. 2009;169(6):542.
FULL TEXT
Hypertriglyceridemia and Its Pharmacologic Treatment Among US Adults—Invited Commentary
Warren G. Thompson and Gerald T. Gau
Arch Intern Med. 2009;169(6):578-579.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Heart Disease and Stroke Statistics--2012 Update: A Report From the American Heart Association
Writing Group Members et al.
Circulation 2012;125:e2-e220.
FULL TEXT
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller et al.
Circulation 2011;123:2292-2333.
FULL TEXT
Rapid Reduction of Severely Elevated Serum Triglycerides with Insulin Infusion, Gemfibrozil and Niacin
Poonuru et al.
Clin Med Res 2011;9:38-41.
ABSTRACT
| FULL TEXT
Heart Disease and Stroke Statistics--2011 Update: A Report From the American Heart Association
Roger et al.
Circulation 2011;123:e18-e209.
FULL TEXT
Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study
Wojczynski et al.
J. Lipid Res. 2010;51:3316-3323.
ABSTRACT
| FULL TEXT
Beyond Low-Density Lipoprotein Cholesterol: Respective Contributions of Non-High-Density Lipoprotein Cholesterol Levels, Triglycerides, and the Total Cholesterol/High-Density Lipoprotein Cholesterol Ratio to Coronary Heart Disease Risk in Apparently Healthy Men and Women
Arsenault et al.
J Am Coll Cardiol 2010;55:35-41.
ABSTRACT
| FULL TEXT
Mutations in HFE Causing Hemochromatosis Are Associated with Primary Hypertriglyceridemia
Solanas-Barca et al.
J. Clin. Endocrinol. Metab. 2009;94:4391-4397.
ABSTRACT
| FULL TEXT
|
